Skip to main content

Advertisement

Table 1 Ex vivo biodistribution of 99m Tc-J591Cdia at 8 h post injection

From: Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA)

Organ DU145-PSMA DU145
Tumour 12.1 ± 1.7 6.3 ± 0.5
Blood 1.5 ± 0.2 1.9 ± 0.4
Stomach 1.4 ± 0.3 2.2 ± 0.1
Small intestine 1.4 ± 0.2 2.4 ± 0.2
Large intestine 1.7 ± 0.3 2.7 ± 0.3
Spleen 10.1 ± 2.8 18.0 ± 1.2
Liver 13.0 ± 1.8 20.5 ± 2.5
Kidneys 29.2 ± 3.5 51.4 ± 3.2
Heart 2.7 ± 0.3 5.8 ± 0.5
Lungs 5.5 ± 1.2 6.0 ± 0.6
Muscle 0.7 ± 0.2 1.3 ± 0.3
Bone 2.0 ± 0.4 4.0 ± 0.4
Reproductive organs 1.8 ± 0.7 3.2 ± 0.4
Salivary glands 2.4 ± 0.7 4.5 ± 0.4
Skin 1.4 ± 0.4 3.1 ± 0.5
Tumour to blood ratio 8 3.3
Tumour to muscle ratio 16.8 4.8
Ratio of DU145-PSMA to DU145 tumour uptake 1.9 -
  1. Ex vivo biodistribution of 99mTc-J591Cdia in mice with subcutaneous DU145 or DU145-PSMA tumours at 8 h post injection (n = 4). Values are expressed as mean percent injected dose per gram of tissue (% ID/g) ± SD.